Envestnet Asset Management Inc. Sells 9,160 Shares of BioNTech SE (NASDAQ:BNTX)

Envestnet Asset Management Inc. decreased its stake in shares of BioNTech SE (NASDAQ:BNTX) by 7.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 121,181 shares of the company’s stock after selling 9,160 shares during the period. Envestnet Asset Management Inc. owned about 0.05% of BioNTech worth $9,738,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares during the last quarter. Covestor Ltd increased its holdings in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of BioNTech during the 1st quarter worth approximately $75,000. Finally, American National Bank purchased a new position in shares of BioNTech in the 1st quarter worth approximately $81,000. Institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BNTX shares. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and lifted their price objective for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and set a $113.00 target price on shares of BioNTech in a research report on Monday, September 16th. JPMorgan Chase & Co. raised BioNTech from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $91.00 to $125.00 in a report on Monday, September 16th. HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Finally, Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $93.00 to $145.00 in a research report on Tuesday. Five analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average price target of $127.15.

BioNTech Price Performance

Shares of BNTX stock opened at $118.22 on Friday. The firm’s 50-day moving average is $93.88 and its two-hundred day moving average is $91.48. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The company has a market capitalization of $28.11 billion, a PE ratio of 236.44 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the previous year, the company posted ($0.86) earnings per share. The company’s revenue was down 23.3% on a year-over-year basis. Analysts predict that BioNTech SE will post -2.87 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.